Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T

2025-11-07 18:08:26 ET

The last time I wrote about Allogene Therapeutics, Inc. ( ALLO ) it was in a Seeking Alpha article entitled "Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products." I noted the company's prospects about its potential registrational phase 2 ALPHA3 trial using its CAR T cemacabtagene Ansegedleucel [cema-cel] for the targeting of 1st-line consolidation Large B-Cell Lymphoma [LBCL] patients. As an update for this program, it is still on track to have a released futility analysis in the 1st half of 2026....

Read the full article on Seeking Alpha

For further details see: